You may be right, though I don't think it was as old as 55.
Nonetheless it generated much lower concentration of antigens than they needed and thus the move to a new formulation and a return to Phase 2 testing.
I'd take from that the point that whilst the technology and approach were not total losses, the implementation had to be re-thought.
|